Skip to main content
ENDO 2026 Main banner

Neuroendocrinology and Pituitary

SAT-013 - LINC 6 Ad Hoc Analysis of New Osilodrostat Users: Improvements in Quality of Life in Patients with Cushing'S Syndrome

Saturday, June 13, 2026
9:30 AM - 4:30 PM CT
Location: ENDOExpo; Poster Floor
Disclosure(s):
Elisabeth Nowak, MD: Esteve: Advisory Board (), Speaker's honoraria ()


Introduction: LINC 6 (NCT05382156) is an ongoing prospective, non-interventional study that evaluates the long-term safety and effectiveness of osilodrostat in patients (pts) with Cushing’s syndrome (CS). This ad hoc analysis describes changes in pt-reported outcomes during osilodrostat treatment.

Methods: The responses of pts (new osilodrostat users) treated for ≥6 months (M) who completed two validated questionnaires – Cushing’s Quality of Life (CushingQoL) questionnaire at baseline (BL) and CushingQoL and/or Patient Global Impression of Change (PGIC) questionnaire 6–18M after treatment initiation – were analyzed. Raw CushingQoL total score ranged from 12 to 60 and was converted into a 0- to 100-point scale; a higher score indicates an improvement in QoL. PGIC score ranged from 1 (very much improved) to 7 (very much worse); pts were categorized into one of three classes based on PGIC assessment: improvement (PGIC ≤3); no change (PGIC = 4); worsening (PGIC ≥5). Analyses are descriptive, with no formal statistical testing.

Results: 29 pts from five countries (USA and Europe) were included (female: n=23, 79.3%; mean [standard deviation] age: 51.0 years [16.4]). Median (min–max) osilodrostat exposure was 14.9M (7.8–26.8). Overall, mean CushingQoL score increased over time (BL: 37.7, n=29; 6–12M: 45.3, n=24; 12–18M: 47.2, n=18). 50.0% (n=14/28) of pts achieved the minimal clinically important difference for CushingQoL (10.1-point change) at least once over 18M. Change from BL in CushingQoL score was moderately correlated with change in mean urinary free cortisol (mUFC) and any cortisol measure (mUFC, late-night salivary cortisol [LNSC] or serum cortisol; r=−0.37 and r=−0.4, respectively). Based on available PGIC responses, 60.9% (n=14/23) and 50.0% (n=8/16) of pts reported that their condition improved from BL to 6–12M and 12–18M, respectively; 17.4% (n=4/23) and 31.3% (n=5/16) reported no change, and 21.7% (n=5/23) and 18.8% (n=3/16) reported worsening in their condition. Mean mUFC and LNSC (x ULN) decreased over time: mUFC (BL: 1.7, n=17; 6–12M: 0.8, n=19; 12–18M: 0.6, n=11); LNSC (BL: 3.2, n=13; 6–12M: 1.3, n=9; 12–18M, 1.0, n=6). Mean serum cortisol (x ULN) remained < ULN (BL: 0.9. n=26; 6–12M: 0.5, n=23; 12–18M: 0.5, n=15). At 6–12M and 12–18M, respectively, 88.9% (n=16/18) and 90.0% (n=9/10) of pts had mUFC ≤ULN, and 44.4% (n=4/9) and 80.0% (n=4/5) had LNSC ≤ULN. Overall, mean systolic blood pressure (mmHg) decreased over time (BL: 137.6, n=28; 6–12M: 129.9, n=22; 12–18M: 118.0, n=13). Mean BMI and HbA1c remained stable over time.

Conclusions: Improvements in QoL were observed in pts with CS during osilodrostat treatment. Biochemical and clinical parameters improved or remained stable over time in most pts.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*